ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Opdivo and Yervoy succeed again, but the US path remains unclear.
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
The company might need something better to replace its ageing blockbuster.
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.